• News

Immunotherapy Drug Can Lower Recurrence When Bladder Cancer Spreads

  • U.S. News & World Report
  • New York, NY
  • (May 16, 2022)

Matthew Galsky, MD, discusses his long-term data from the phase 3 CheckMate 274 trial evaluating adjuvant nivolumab vs placebo in patients with high-risk, muscle-invasive urothelial cancer. He said, “These results support adjuvant nivolumab as a standard of care for high-risk [patient with] muscle-invasive urothelial carcinoma after radical surgery.

Learn more